Muscle Growth Drug Mitigates Lean Mass Loss with Weight

A recent trial indicates that a muscle growth-promoting drug can reduce lean body mass loss when administered concurrently with GLP-1 based weight-loss medications. This addresses a known side effect of GLP-1 agonists, which can lead to a significant reduction in lean tissue alongside fat loss.

The study involved a monoclonal antibody, apitegromab, which targets myostatin, a protein that inhibits muscle growth. Participants receiving apitegromab alongside tirzepatide experienced 55% greater retention of lean mass compared to a placebo group.

While total weight loss remained consistent across both

While total weight loss remained consistent across both groups, the differential impact on lean mass is significant for patient health outcomes. Lean body mass is crucial for physical strength, metabolic function, and overall health.

However, the trial was limited in size and duration, and predominantly involved women. Further large-scale, long-term studies are required to confirm efficacy, assess long-term safety, and determine the clinical benefits on patient functionality and health.